CA2908731A1 - Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction - Google Patents

Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Info

Publication number
CA2908731A1
CA2908731A1 CA2908731A CA2908731A CA2908731A1 CA 2908731 A1 CA2908731 A1 CA 2908731A1 CA 2908731 A CA2908731 A CA 2908731A CA 2908731 A CA2908731 A CA 2908731A CA 2908731 A1 CA2908731 A1 CA 2908731A1
Authority
CA
Canada
Prior art keywords
bimatoprost
composition
fat
sustained release
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2908731A
Other languages
English (en)
French (fr)
Inventor
Scott M. Whitcup
Patrick M. Hughes
David F. Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2908731A1 publication Critical patent/CA2908731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
CA2908731A 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction Abandoned CA2908731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
US61/811,682 2013-04-12
PCT/US2014/033558 WO2014169075A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Publications (1)

Publication Number Publication Date
CA2908731A1 true CA2908731A1 (en) 2014-10-16

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2908731A Abandoned CA2908731A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Country Status (18)

Country Link
US (2) US20140308354A1 (https=)
EP (2) EP2983663B1 (https=)
JP (1) JP2016520561A (https=)
KR (1) KR20150141972A (https=)
CN (2) CN110840899A (https=)
AU (2) AU2014250937A1 (https=)
BR (1) BR112015025915A8 (https=)
CA (1) CA2908731A1 (https=)
CL (1) CL2015003023A1 (https=)
DK (1) DK2983663T3 (https=)
ES (1) ES2785382T3 (https=)
IL (1) IL242006B (https=)
MX (1) MX381097B (https=)
MY (1) MY187802A (https=)
RU (1) RU2015143859A (https=)
SG (2) SG10202109919PA (https=)
WO (1) WO2014169075A1 (https=)
ZA (1) ZA201507217B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176640A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
CN120731079A (zh) * 2023-04-18 2025-09-30 维乐菲尔概念有限公司 用于诱导黄体溶解的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1996036599A1 (en) * 1995-05-18 1996-11-21 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
NZ539582A (en) 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
CN101336887A (zh) * 2002-12-04 2009-01-07 参天制药株式会社 结膜下给药用药物组合物
JP2007515494A (ja) * 2003-12-22 2007-06-14 アベンティス・ファーマスーティカルズ・インコーポレイテツド 注射可能なフォスファチジルコリン調製物
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
US20120022137A1 (en) 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
WO2014143754A2 (en) * 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Also Published As

Publication number Publication date
ES2785382T3 (es) 2020-10-06
DK2983663T3 (da) 2020-04-20
EP2983663B1 (en) 2020-01-22
ZA201507217B (en) 2017-09-27
AU2019203214B2 (en) 2020-10-29
CN105101962A (zh) 2015-11-25
JP2016520561A (ja) 2016-07-14
WO2014169075A1 (en) 2014-10-16
RU2015143859A (ru) 2017-05-16
CL2015003023A1 (es) 2016-06-10
RU2015143859A3 (https=) 2018-03-05
BR112015025915A8 (pt) 2020-01-14
KR20150141972A (ko) 2015-12-21
SG10202109919PA (en) 2021-10-28
HK1221406A1 (en) 2017-06-02
IL242006B (en) 2020-04-30
BR112015025915A2 (pt) 2017-07-25
SG10201701938PA (en) 2017-04-27
US10682361B2 (en) 2020-06-16
MY187802A (en) 2021-10-26
US20160339039A1 (en) 2016-11-24
MX2015014320A (es) 2015-12-08
CN110840899A (zh) 2020-02-28
NZ712804A (en) 2021-02-26
MX381097B (es) 2025-03-12
US20140308354A1 (en) 2014-10-16
AU2014250937A1 (en) 2015-10-22
EP3656375A1 (en) 2020-05-27
EP2983663A1 (en) 2016-02-17
AU2019203214A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US11944717B2 (en) Devices for in situ formed nerve caps and/or nerve wraps
Packhaeuser et al. In situ forming parenteral drug delivery systems: an overview
AU2019203214B2 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
EP1581181B1 (en) Controlled release depot formulations
JP2005538107A5 (ja) 注入可能な多モードポリマーのデポ組成物及びその使用
EP2067468A1 (en) Sustained release dosage forms of anesthetics for pain management
US20210361292A1 (en) Methods for in situ formed nerve cap with rapid release
CA2973374A1 (en) Joint fat pad formulations, and methods of use thereof
CA3163429A1 (en) Methods and devices for in situ formed nerve cap with rapid release
JP2016520561A5 (https=)
HK40031326A (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
HK40025309A (en) Subtained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
NZ712804B2 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
HK1221406B (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
EP3986491B1 (en) Crosslinkable hydrogel compositions
Boesel et al. Injectable biodegradable systems
KR20230022737A (ko) 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트
HK1085387B (en) Controlled release depot formulations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190402

FZDE Discontinued

Effective date: 20211022